

Niccolo E Mencacci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8800674/publications.pdf>

Version: 2024-02-01

82
papers

5,645
citations

117625

34
h-index

95266

68
g-index

87
all docs

87
docs citations

87
times ranked

7791
citing authors

#	ARTICLE	IF	CITATIONS
1	Biallelic <i>AOPEP</i> Loss-of-Function Variants Cause Progressive Dystonia with Prominent Limb Involvement. <i>Movement Disorders</i> , 2022, 37, 137-147.	3.9	14
2	Clinical Reasoning: A 77-Year-Old Man With Involuntary Movements, Sleep Changes, Falls, Bulbar Symptoms, and Cognitive Complaints. <i>Neurology</i> , 2022, 99, 26-30.	1.1	2
3	<i>EIF2AK2</i> Missense Variants Associated with Early Onset Generalized Dystonia. <i>Annals of Neurology</i> , 2021, 89, 485-497.	5.3	32
4	Replication assessment of <i>NUS1</i> variants in Parkinson's disease. <i>Neurobiology of Aging</i> , 2021, 101, 300.e1-300.e3.	3.1	3
5	Community-based genetic study of Parkinson's disease in Estonia. <i>Acta Neurologica Scandinavica</i> , 2021, 143, 89-95.	2.1	3
6	Emerging and converging molecular mechanisms in dystonia. <i>Journal of Neural Transmission</i> , 2021, 128, 483-498.	2.8	29
7	<i>MED27</i> Variants Cause Developmental Delay, Dystonia, and Cerebellar Hypoplasia. <i>Annals of Neurology</i> , 2021, 89, 828-833.	5.3	14
8	Genetic Dystonias: Update on Classification and New Genetic Discoveries. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 8.	4.2	32
9	<i>YY1</i> -Related Dystonia: Clinical Aspects and Long-Term Response to Deep Brain Stimulation. <i>Movement Disorders</i> , 2021, 36, 1461-1462.	3.9	16
10	Biallelic variants in <i>TSPOAP1</i> , encoding the active-zone protein <i>RIMBP1</i> , cause autosomal recessive dystonia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	18
11	Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets. <i>JAMA Neurology</i> , 2021, 78, 464.	9.0	95
12	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. <i>Annals of Neurology</i> , 2021, 90, 35-42.	5.3	29
13	Childhood-Onset Chorea Caused by a Recurrent De Novo <i>DRD2</i> Variant. <i>Movement Disorders</i> , 2021, 36, 1472-1473.	3.9	6
14	The Emerging Role of Phosphodiesterases in Movement Disorders. <i>Movement Disorders</i> , 2021, 36, 2225-2243.	3.9	21
15	The global Parkinson's Genetics Program (GP2): The Monogenic Hub 500-genomes pilot project. <i>Journal of the Neurological Sciences</i> , 2021, 429, 118257.	0.6	0
16	Monogenic portal of the global Parkinson's Genetics Program (GP2). <i>Journal of the Neurological Sciences</i> , 2021, 429, 118256.	0.6	0
17	The commercial genetic testing landscape for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 92, 107-111.	2.2	16
18	Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome. <i>Nature Communications</i> , 2021, 12, 7342.	12.8	44

#	ARTICLE	IF	CITATIONS
19	Dystonia genes functionally converge in specific neurons and share neurobiology with psychiatric disorders. <i>Brain</i> , 2020, 143, 2771-2787.	7.6	50
20	Loss of Function Variants in <i>HOPS</i> Complex Genes <i>VPS16</i> and <i>VPS41</i> Cause Early Onset Dystonia Associated with Lysosomal Abnormalities. <i>Annals of Neurology</i> , 2020, 88, 867-877.	5.3	70
21	Penetrance of Parkinson's Disease in <i>LRRK2</i> p.G2019S Carriers Is Modified by a Polygenic Risk Score. <i>Movement Disorders</i> , 2020, 35, 774-780.	3.9	57
22	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. <i>Lancet Neurology</i> , The, 2019, 18, 1091-1102.	10.2	1,414
23	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. <i>Movement Disorders</i> , 2019, 34, 1851-1863.	3.9	47
24	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 460-468.	3.9	66
25	Frequency and phenotypic spectrum of <i>KMT2B</i> dystonia in childhood: A single-center cohort study. <i>Movement Disorders</i> , 2019, 34, 1516-1527.	3.9	55
26	A Novel SGCE Nonsense Variant Associated With Marked Intrafamilial Variability in a Turkish Family With Myoclonus-Dystonia. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 479-482.	1.5	3
27	Mitochondrial complex I NUBPL mutations cause combined dystonia with bilateral striatal necrosis and cerebellar atrophy. <i>European Journal of Neurology</i> , 2019, 26, 1240-1243.	3.3	9
28	KCTD17 is a confirmed new gene for dystonia, but is it responsible for SGCE-negative myoclonus-dystonia?. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 1-3.	2.2	10
29	Dystonia; a roadmap is needed for future genetic studies. <i>Parkinsonism and Related Disorders</i> , 2019, 58, 9-11.	2.2	1
30	Restless Legs Syndrome in NKX2-1-related chorea: An expansion of the disease spectrum. <i>Brain and Development</i> , 2019, 41, 250-256.	1.1	6
31	Naming Genes for Dystonia: DYT-z or Ditz?. <i>Tremor and Other Hyperkinetic Movements</i> , 2019, 9, .	2.0	0
32	Recessive mutations in <i>VPS13D</i> cause childhood onset movement disorders. <i>Annals of Neurology</i> , 2018, 83, 1089-1095.	5.3	104
33	Oculomotor apraxia and disrupted sleep with nocturnal ballistic bouts in ADCY5-related disease. <i>Parkinsonism and Related Disorders</i> , 2018, 54, 103-106.	2.2	10
34	A homozygous loss of function mutation in <i>PDE2A</i> associated to early onset hereditary chorea. <i>Movement Disorders</i> , 2018, 33, 482-488.	3.9	52
35	LRP10 in α -synucleinopathies. <i>Lancet Neurology</i> , The, 2018, 17, 1032.	10.2	15
36	PDE10A and ADCY5 mutations linked to molecular and microstructural basal ganglia pathology. <i>Movement Disorders</i> , 2018, 33, 1961-1965.	3.9	38

#	ARTICLE	IF	CITATIONS
37	Dystonia. Nature Reviews Disease Primers, 2018, 4, 25.	30.5	223
38	Partial loss-of-function of sodium channel SCN8A in familial isolated myoclonus. Human Mutation, 2018, 39, 965-969.	2.5	34
39	PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease. Movement Disorders, 2017, 32, 219-226.	3.9	59
40	ADCY5-related movement disorders: Frequency, disease course and phenotypic variability in a cohort of paediatric patients. Parkinsonism and Related Disorders, 2017, 41, 37-43.	2.2	67
41	Mutations in the histone methyltransferase gene KMT2B cause complex early-onset dystonia. Nature Genetics, 2017, 49, 223-237.	21.4	186
42	Emerging Monogenic Complex Hyperkinetic Disorders. Current Neurology and Neuroscience Reports, 2017, 17, 97.	4.2	51
43	A <i>PDE10A</i> de novo mutation causes childhood-onset chorea with diurnal fluctuations. Movement Disorders, 2017, 32, 1646-1647.	3.9	13
44	GBA-Associated Parkinson's Disease: Progression in a Deep Brain Stimulation Cohort. Journal of Parkinson's Disease, 2017, 7, 635-644.	2.8	44
45	Neurodegeneration With Brain Iron Accumulation (NBIA) Syndromes Presenting With Late-Onset Craniocervical Dystonia: An Illustrative Case Series. Movement Disorders Clinical Practice, 2017, 4, 254-257.	1.5	6
46	The Endless Expansion of the Phenotypic Spectrum of <i>ATP1A3</i> Mutations: A True Diagnostic Challenge. Movement Disorders Clinical Practice, 2016, 3, 395-397.	1.5	0
47	Recent advances in genetics of chorea. Current Opinion in Neurology, 2016, 29, 486-495.	3.6	25
48	De Novo Mutations in PDE10A Cause Childhood-Onset Chorea with Bilateral Striatal Lesions. American Journal of Human Genetics, 2016, 98, 763-771.	6.2	96
49	A genome-wide association study in multiple system atrophy. Neurology, 2016, 87, 1591-1598.	1.1	139
50	<i>SLC25A46</i> mutations underlie progressive myoclonic ataxia with optic atrophy and neuropathy. Movement Disorders, 2016, 31, 1249-1251.	3.9	49
51	Mitofusin-mediated ER stress triggers neurodegeneration in pink1/parkin models of Parkinson's disease. Cell Death and Disease, 2016, 7, e2271-e2271.	6.3	151
52	Analysis of the genetic variability in Parkinson's disease from Southern Spain. Neurobiology of Aging, 2016, 37, 210.e1-210.e5.	3.1	23
53	Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data. Lancet Neurology, The, 2016, 15, 585-596.	10.2	77
54	<i>ADCY5</i> mutations are another cause of benign hereditary chorea. Neurology, 2016, 86, 978-979.	1.1	4

#	ARTICLE	IF	CITATIONS
55	Web-based assessment of Parkinson's prodromal markers identifies GBA variants. <i>Movement Disorders</i> , 2015, 30, 1002-1003.	3.9	6
56	Expanding the Phenotype and Genetic Defects Associated with the <i>GOSR2</i> Gene. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 271-273.	1.5	21
57	A Missense Mutation in KCTD17 Causes Autosomal Dominant Myoclonus-Dystonia. <i>American Journal of Human Genetics</i> , 2015, 96, 938-947.	6.2	109
58	HABC syndrome and DYT4: Variable expressivity or pleiotropy of TUBB4 mutations?. <i>Movement Disorders</i> , 2015, 30, 828-833.	3.9	117
59	Reply: Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. <i>Brain</i> , 2015, 138, e352-e352.	7.6	4
60	<i>ADCY5</i> mutations are another cause of benign hereditary chorea. <i>Neurology</i> , 2015, 85, 80-88.	1.1	140
61	The <i>CACNA1B</i> R1389H variant is not associated with myoclonus-dystonia in a large European multicentric cohort. <i>Human Molecular Genetics</i> , 2015, 24, 5326-5329.	2.9	28
62	Persistent chorea in DYT6, due to anticholinergic therapy. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1282-1283.	2.2	8
63	Cortical pencil lining in neuroferritinopathy: A diagnostic clue. <i>Neurology</i> , 2015, 84, 1816-1818.	1.1	93
64	All in the blink of an eye: new insight into cerebellar and brainstem function in <i>DYT1</i> and <i>DYT6</i> dystonia. <i>European Journal of Neurology</i> , 2015, 22, 762-767.	3.3	38
65	Long-term Clinical Outcome of Fetal Cell Transplantation for Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 83.	9.0	257
66	Paroxysmal Kinesigenic Dyskinesia May Be Misdiagnosed in Co-occurring Gilles de la Tourette Syndrome. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 84-86.	1.5	11
67	Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. <i>Brain</i> , 2014, 137, 2480-2492.	7.6	169
68	Screening of mutations in NOL3 in a myoclonic syndromes series. <i>Journal of Neurology</i> , 2014, 261, 1830-1831.	3.6	1
69	Ropinirole monotherapy induced severe reversible dyskinesias in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1159-1160.	3.9	6
70	The glucocerebrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. <i>Movement Disorders</i> , 2013, 28, 232-236.	3.9	121
71	Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. <i>Brain</i> , 2013, 136, 392-399.	7.6	266
72	Oligoclonal bands in the cerebrospinal fluid of amyotrophic lateral sclerosis patients with disease-associated mutations. <i>Journal of Neurology</i> , 2013, 260, 85-92.	3.6	24

#	ARTICLE	IF	CITATIONS
73	Parkin Disease. JAMA Neurology, 2013, 70, 571.	9.0	119
74	Mutations in the autoregulatory domain of β -tubulin 4a cause hereditary dystonia. Annals of Neurology, 2013, 73, 546-553.	5.3	148
75	Genotype and phenotype in Parkinson's disease: Lessons in heterogeneity from deep brain stimulation. Movement Disorders, 2013, 28, 1370-1375.	3.9	77
76	Dopaminergic Neuronal Imaging in Genetic Parkinson's Disease: Insights into Pathogenesis. PLoS ONE, 2013, 8, e69190.	2.5	55
77	Myoclonus-dystonia syndrome due to tyrosine hydroxylase deficiency. Neurology, 2012, 79, 435-441.	1.1	45
78	Intracerebral haemorrhage, a possible presentation in Churg-Strauss syndrome: Case report and review of the literature. Journal of the Neurological Sciences, 2011, 301, 107-111.	0.6	19
79	Atypical Parkinsonism Revealing a Late Onset, Rigid and Akinetic Form of Huntington's Disease. Case Reports in Neurological Medicine, 2011, 2011, 1-3.	0.4	5
80	Low anaerobic threshold and increased skeletal muscle lactate production in subjects with Huntington's disease. Movement Disorders, 2011, 26, 130-137.	3.9	52
81	Metalloproteinase alterations in the bone marrow of ALS patients. Journal of Molecular Medicine, 2010, 88, 553-564.	3.9	30
82	Aripiprazole in the treatment of Huntington's disease: a case series. Neuropsychiatric Disease and Treatment, 2009, 5, 1-4.	2.2	34